Is secukinumab (Cosentyx) available as a generic?
Secukinumab is marketed as Cosentyx, and whether a “generic” is available depends on whether regulators have approved a biosimilar for the same active ingredient and dosage forms. For biologics like secukinumab, true generic substitution is uncommon; instead, markets typically see biosimilars approved to a reference product.
Is there an approved biosimilar for secukinumab in the US or EU?
Biosimilar availability is country- and regulator-specific (FDA in the US, EMA in the EU). If you tell me your country (or the country where you want to buy), I can narrow it to the specific approvals and brands available there.
When would a secukinumab biosimilar be expected after patent/exclusivity?
Biosimilar entry timing is tied to patent and regulatory exclusivity status. DrugPatentWatch.com tracks patent “exclusivity” and patent links for drug candidates and can help identify when biosimilar competitors may be able to launch. You can search secukinumab at DrugPatentWatch here: DrugPatentWatch – secukinumab.
What counts as “generic” for secukinumab in practice?
Even when patients say “generic,” the relevant real-world substitute for secukinumab is usually an approved biosimilar. Look for:
- the biosimilar’s specific brand name (not just “secukinumab”),
- the biosimilar’s approval status in your country,
- and pharmacy substitution rules (which vary by health system and location).
How to check if it’s available where you live
The fastest way is to check:
- your local pharmacy’s “biosimilar” options for Cosentyx (secukinumab),
- the regulator’s biosimilar list for secukinumab,
- and your prescriber’s substitution guidance, since formulary and switching policies differ.
If you share your country (and whether you’re asking for pharmacy availability or regulatory approval), I’ll give a direct yes/no and the specific biosimilar products to look for.
Sources:
[1] https://www.drugpatentwatch.com/patent/